Your browser doesn't support javascript.
loading
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey, W Timothy; Frias, Juan P; Jastreboff, Ania M; le Roux, Carel W; Sattar, Naveed; Aizenberg, Diego; Mao, Huzhang; Zhang, Shuyu; Ahmad, Nadia N; Bunck, Mathijs C; Benabbad, Imane; Zhang, Xiaotian M.
Afiliação
  • Garvey WT; UAB Diabetes Research Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: garveyt@uab.edu.
  • Frias JP; Velocity Clinical Research, Los Angeles, CA, USA.
  • Jastreboff AM; Department of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT, USA.
  • le Roux CW; Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland; Diabetes Research Centre, Ulster University, Coleraine, UK.
  • Sattar N; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
  • Aizenberg D; Centro Médico Viamonte, Buenos Aires, Argentina.
  • Mao H; Eli Lilly and Company, Indianapolis, IN, USA.
  • Zhang S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Ahmad NN; Eli Lilly and Company, Indianapolis, IN, USA.
  • Bunck MC; Eli Lilly and Company, Indianapolis, IN, USA.
  • Benabbad I; Eli Lilly and Company, Indianapolis, IN, USA.
  • Zhang XM; Eli Lilly and Company, Indianapolis, IN, USA.
Lancet ; 402(10402): 613-626, 2023 08 19.
Article em En | MEDLINE | ID: mdl-37385275

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Idioma: En Ano de publicação: 2023 Tipo de documento: Article